

Solos Endoscopy, Inc. Successfully introduces MammoView at the Annual Conference of Association of Breast Surgeons of India

WESTPORT, CT--(PRNewswire)—September 23, 2019 -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce a successful introduction of its MammoView ductoscopy products at the 8th Annual Conference of Association of Breast Surgeons of India (ABSICON), which was held earlier this month. This conference has been designed to provide medical professionals with a comprehensive update on the latest research and medical advances in the treatment of breast cancer. The Association of Breast Surgeons of India (ABSI) represents General Surgeons, Surgical Oncologists and Plastic Surgeons who treat patients with breast disease. This annual event aims to bring together leading academic scientists and researchers to exchange and share their experiences and research results. It also provides a premier inter-multi-trans-disciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends and concerns, practical challenges encountered, and solutions adopted in the field of breast disease management.

“This was an ideal venue for us to showcase our advanced non-invasive MammoView products to the international medical market. We expect to create valuable relationships with the medical professionals who are actively fighting the battle against breast cancer. and our ductoscopy products could play an important role,” stated Joe Gassman, International Sales Consultant for Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarts.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700